Background
==========

Single nucleotide polymorphisms (SNPs), changes in a single base pair of the DNA sequence, are the most frequently occurring form of variation in the human genome. Many genes have a large number of SNPs, and it is acknowledged that there are more than 10 million SNPs across the human genome, making it impossible for cost-effective genotyping of all of them in studies of disease, even in very small samples. We can, however, reduce the genotyping burden by exploiting the strong correlation between some SNPs that are close together on the genome. This is due to the phenomenon of linkage disequilibrium (LD), or non-random association of SNP alleles at the population level, due to the sharing by multiple individuals of ancestral chromosomal segments. These segments, or haplotypes, are combinations of particular SNP alleles on the same chromosome that tend to segregate together. By choosing a subset of maximally informative SNPs, or \"tag\" SNPs, to represent these haplotypes, the number of SNPs to be genotyped in a larger sample can be reduced without losing the ability to capture most of the variation, and in particular any association between unmeasured \"causal\" alleles and the disease outcome measured on individuals in the sample. This is an increasingly common approach to genetic association studies, since it reduces costs but retains much of the information about linkage disequilibrium patterns across the human genome. It is the underlying principle behind the HapMap \[[@B1]\] project. An additional assumption behind this approach is the idea of the common variant common disease hypothesis. It is assumed that the variant, and hence its haplotype, are relatively common in the general population and hence will be ascertained using this approach. If, however, the disease is caused by a rare variant, this approach may fail to detect association.

Many researchers are now turning to large, publicly available databases of SNPs, which provide a catalogue of human genetic variation, in order to choose a set of informative \"tag\" SNPs for genotyping in association studies of disease. The International HapMap Project \[[@B2]\] and the Seattle SNPs project are complemented by several NIH initiatives including the National Institute of Environmental Health Sciences Environmental Genome Project (NIEHS EGP) and the National Heart Lung and Blood Institute Resequencing and Genotyping Project. The choice of tag SNPs is made more challenging when study subjects are from multiple populations, since the transferability of tag SNPs depends on similarity of linkage disequilibrium patterns. It is also desirable to incorporate resequencing data from local case and control samples generated during a \"SNP discovery\" phase. A further complication is the need for the chosen tag SNPs to have high probability of successfully being genotyped on the high-throughput platform being used to process the samples.

Iron is essential for life and consequently body iron levels are tightly regulated in humans. There are disease states associated with having either too little (iron deficiency) or too much (iron overload) iron, the former usually due to inadequate dietary iron or excessive iron loss and the latter usually associated with mutations in proteins that regulate intestinal iron absorption. About 90% of clinical cases of iron overload (hemochromatosis) in populations of northern European origin are homozygous for the 845 G → A mutation in the *HFE*gene responsible for the C282Y substitution in the HFE protein \[[@B3]\]. Affected individuals are characterised by high transferrin saturation (a measure of the amount of circulating iron), an increased serum ferritin (a measure of iron storage) and the associated clinical symptoms of iron overload (fatigue, arthritis, abnormal liver function and ultimately permanent tissue damage). Despite the high prevalence of mutations in the *HFE*gene, the phenotypic expression of hemochromatosis varies considerably and both environmental and genetic factors appear to make important contributions to this variation. The *HealthIron*Study seeks to find associations in Caucasian subjects between common polymorphisms in candidate genes of iron metabolism and variations in the iron phenotype in HFE-associated hemochromatosis.

Here we describe the methods used to select SNPs for genotyping of samples from the HealthIron Study on the basis of sequence data available from a number of different sources, both public and proprietary, with particular reference to iron homeostasis genes. The selected SNPs were subsequently genotyped using the Illumina platform which genotypes one to four multiples of 384 SNPs in a multiplex reaction. A goal of this research was to identify 384 SNPs based on a consideration of 35 genes involved in iron metabolism.

Methods
=======

We used four data sources in order to obtain thorough SNP coverage of the genes and to allow detection of either direct association between iron phenotypes and a causal variant or indirect association with a marker that is in linkage disequilibrium (LD) with a causal variant. We used a minor allele frequency (MAF) cut-off of ≥ 3% and r^2^(the square of the correlation between SNPs) of 0.8. The MAF cut-off of ≥ 3% was chosen as a compromise between power (i.e. sample size, 3% represents 6 heterozygotes among 94 individuals sequenced) and detection of rare alleles with large effect.

The four data sets used were:

**1. HealthIron:**Resequencing of selected candidate genes has been performed on two groups of individuals of northern European descent (94 C282Y homozygotes and 94 chosen randomly without regard to *HFE*genotype) from a large population-based cohort study \[[@B4]\]. We report here only on the randomly chosen individuals who were resequenced for six genes.

**2. HEIRS ancillary study NHLBI:**The Hemochromatosis and Iron Overload Screening \[[@B5]\] (HEIRS), ancillary study on iron deficiency carried out initial SNP identification from 14 candidate genes by resequencing of five populations: 24 African American, 24 Yorubans (HapMap YRI), 47 Caucasian with north-west European ancestry (HapMap CEU), 48 Hispanic descent, 45 Chinese (HapMap CHB). This resequencing was completed by the Resequencing and Genotyping Service of the National Heart Lung and Blood Institute (NHLBI RS&G). Accession numbers are TFR2: DQ496110, TF: DQ525716, HFE2: DQ309445, HCP1: DQ496103, TFRC: DQ496099, PGRMC2: DQ496105, PGRMC1: DQ496104, IREB2: DQ496102, HEPH: DQ496100, HAMP: DQ496109, FTH1: DQ496108, FLVCR: DQ496107, CYBRD1: DQ496101, and ACO1: DQ496106.

**3. SeattleSNPs**\[[@B6]\]: This is funded as part of the NHLBI Programs for Genomic Applications (PGA). It aims to investigate the associations between SNPs in candidate genes and pathways that underlie inflammatory responses in humans. Individual investigators can nominate candidate genes to be resequenced for SNP discovery. Three of the genes of iron metabolism targeted by the HealthIron and HEIRS ancillary projects have been resequenced by SeattleSNPs (TF, HMOX1, TNFα all panel 1: 23 CEPH (9 are HapMap children), 24 African Americans -- which are the same as in the HEIRS ancillary study).

**4. HapMap**(publicly available \[[@B7]\]): The International HapMap Project \[[@B2]\] is analyzing DNA from populations with African, Asian, and European ancestry to generate a catalogue of common SNPs across the whole genome in humans.

Tag SNP selection programs
--------------------------

There are many algorithms and software packages designed to select tag SNPs from large arrays of genotype data. We review briefly the two packages that we used to select a subset of SNPs for further genotyping in a larger sample of individuals from our cohort study.

LDSelect
--------

The *LDselect*algorithm \[[@B8],[@B9]\] partitions the SNPs into \"bins\", that is, each SNP is a member of one and only one bin. In a given bin there is at least one SNP that has a pairwise r^2^exceeding a user-specific threshold (*e.g*. 80%) with each of the other SNPs in that same bin, where r^2^is the correlation between two SNPs calculated using the genotype data available from one of the data sources. There may be several such tag SNPs in each bin, but not all SNPs in each bin are necessarily tag SNPs for that bin; it is possible that some pairs of SNPs in the same bin have pairwise r^2^values that do not exceed the threshold. Each of the tag SNPs in a particular bin can be used to represent the allelic variation of SNPs within each bin, and is a candidate for genotyping in a larger sample.

Tagger in Haploview
-------------------

The *Tagger*software begins by using a tagging algorithm similar to LDselect, where SNPs are captured by requiring pairwise association with at least one of a series of single tagging markers at a prescribed threshold value of the pairwise correlation r^2^(software available as part of Haploview \[[@B10]\]). Tagger then seeks to further reduce the number of tag SNPs by attempting to replace each tag with a multi-marker predictor based on the remaining tag SNPs. Any proposed multi-marker combination is checked to ensure that it can capture the SNPs originally represented by the replaced tag SNP with a value of r^2^exceeding the prescribed threshold, and if not, the original tag SNP is retained. Further details can be found in de Bakker et al. \[[@B11]\] and Barrett et al. \[[@B10]\].

Challenge with Illumina platform -- validation scores
-----------------------------------------------------

The Illumina corporation use an algorithm (accessed via a service provided free of charge to prospective clients) to generate a validation score for a specified SNP. The validation score, which takes values between 0 and 1, is calculated from the 200 base pair genetic sequence surrounding each SNP. It is an estimate of the likelihood that an assay for that SNP will work successfully, i.e. genotype most individuals accurately. If the SNP has previously been successfully genotyped on the Illumina platform the SNP is given a validation score of 1.1 and it becomes a so-called \"Golden Gate\" SNP. Illumina recommends not using SNPs with validation scores below 0.6, and including additional SNPs for redundancy to overcome loss of information due to SNP failure even for SNPs with high validation scores. SNPs within 60 bp of each other and tri-allelic SNPs cannot be typed.

We attempted to satisfy the requirement of genotyping only SNPs with high validation scores and to incorporate redundancy by (i) selecting tag SNPs separately from each dataset where sequence data for a gene was available from more than one data source and (ii) selecting additional tag SNPs to be genotyped in large bins in case the first tag SNP failed. The selection of high validation score SNPs should increase the genotyping rate and minimise the chance of assay failure. It is straightforward to incorporate these rules into the selection process when using LDselect which lists all the alternative tag SNPs for each bin. Therefore it is necessary to run the program only once and choose the highest validation score SNP from the nominated alternative tag SNPs (provided at least one tag SNP has validation score \> 0.6), since changing the selection of one or more tag SNPs within a bin does not affect the selection process of tag SNPs in the other bins. We also took advantage of the alternate tagSNP listing from LDselect to choose a second redundant tagSNP for large bins in case the first tagSNP assay failed.

In contrast, this is not possible using Tagger, although Tagger now has the ability to exclude SNPs from consideration as tags, ensuring that all chosen tag SNPs have validation scores above 0.6. Tagger does not provide a list of alternative tag SNPs (or combinations of tag SNPs) from which one could choose those with the highest validation score. It is possible that another selection of tag SNPs would perform equally well in capturing allelic variation in the gene at the given r^2^threshold with uniformly better validation scores. The only way one could check this is to further exclude SNPs with lower validation scores, rerun the program, and determine whether the next selection of tag SNPs all have higher validation scores while still satisfying the r^2^threshold. Clearly this has the potential to affect the combination of tag SNPs selected and the groups of SNPs represented by them.

Results
=======

A total of 35 genes (see Table [1](#T1){ref-type="table"}) were chosen for examination and genotyping in subjects from the HealthIron study. This selection was based on prior biological evidence for involvement in iron metabolism. Some of these genes have strong historical evidence of involvement in cellular iron uptake and storage (*TF, TFRC, FTH1, FTL*) whereas others were chosen based on more recent evidence (*SLC40A1, SLC11A2, CP, TFR2, CYBRD1, IREB2, HFE2, HEPH, HEPHL1, HAMP, HCP1, DHCR7, HP, HMOX1*). Several genes (*CUBN*, *STEAP3*and *EXOC6*) were not completely covered i.e. not all the required tag SNPs were included as we had reached our total of 384 SNPs.

###### 

HealthIron SNPs selected for typing by gene, incomplete cover means not all tag SNPs were included.

  No. SNPs        HUGO       Full or other name(s)                        Chr
  ---------- ---- ---------- -------------------------------------------- ----------
  16         \*   ACO1       IRP1; IRE-binding protein; Aconitase 1       9p21.2
  1               CALR       Calreticulin                                 19p13.13
  14              CD163      Hemoglobin scavenger receptor                12p13.31
  25              CP         Ceruloplasmin                                3q25.1
  29              CUBN       Cubulin (incomplete cover)                   10p13
  27         \*   CYBRD1     Dcytb                                        2q31.1
  6               DHCR7      Smith-Lemli-Opitz syndrome                   11q13.4
  3               EXOC6      SEC15 (incomplete cover)                     10q23.33
  16              FLVCR      Feline leukemia virus subgroup C receptor    1q32.3
  7          \*   FTH1       H-ferritin                                   11q12.3
  1               FTL        L-Ferritin                                   19q13.33
  7               FXN        Frataxin                                     9q21.11
  2               GAST       Gastrin                                      17q21.2
  1               GSTP1      GSTP1 I105V                                  11q13.2
  5          \*   HAMP       Hepcidin                                     19q13.12
  5          \*   HCP1       MGC9564, heme carrier protein 1              17q11.2
  18         \*   HEPH       Hephaestin                                   Xq12
  9               HEPHL1     Hephaestin-like 1; Eleutherin                11q21
  7               HFE        Hemochromatosis                              6p22.2
  4          \*   HFE2       Hemojuvelin                                  1q25
  10              HMOX1      HO-1Hemoxygenase 1                           22q12.3
  2               HMOX2      HO-2 Hemoxygenase 2                          16p13.3
  2               HP         Haptoglobin                                  16q22.2
  6               HPX        Hemopexin                                    11p15.4
  18         \*   IREB2      IRP2 IRE-binding protein 2                   15q24.1
  1          \*   PGRMC1     Progesterone receptor membrane component 1   Xq24
  3          \*   PGRMC2     Progesterone receptor membrane component 2   4q28.2
  13              SLC11A2    Divalent metal-ion transporter 1; DCT1       12q13.12
  20              SLC25A37   Frascati                                     8p21.2
  12              SLC40A1    Ferroportin; IREG1; MTP1                     2q32.2
  11              STEAP3     nm1058 (incomplete cover)                    2q14.2
  45         \*   TF         Transferrin                                  3q22.1
  6          \*   TFR2       Transferrin receptor 2                       7q22.1
  30         \*   TFRC       Transferrin receptor 1                       3q29
  2               TNF        TNFalpha                                     6p21.33
  384                                                                     

\* indicates genes where NHBLI RS&G Caucasian data was used.

A substantial percentage of SNPs (41%) we submitted for validation had scores below 0.6, and were excluded from being selected as tag SNPs. This meant coverage of SNPs was not complete, although in regions with high LD there was usually an alternative SNP to tag those with low validation scores. A second round of genotyping on a different platform will be performed for the HealthIron Study to attempt to capture these low validation uncaptured SNPs. Figure [1](#F1){ref-type="fig"} shows that the relationship between validation scores for SNPs and \"Gentrain\" score (a measure of SNP performance automatically calculated by the Illumina BeadStudio software) is not strong. Half of the ten \"unscorable\" SNPs were Golden Gate validated (previously successful), i.e. given scores of 1.1; overall 35% of our selected SNPs had scores of 1.1. This suggests that validation/design scores above 0.6 do not predict genotyping performance, and that maximising average validation score may not have a large effect on SNP success rate.

![**Scatter plot of SNP validation scores with Gentrain scores**. Previously successful SNPs are given a score of 1.1, design scores between 0 and 1 are calculated by a proprietary algorithm based on the surrounding 200 bp.](1471-2350-9-18-1){#F1}

Table [2](#T2){ref-type="table"} displays, for each gene and for data on Caucasian individuals only from each data source, a comparison of the number of tag SNPs selected by LDselect versus Tagger in Haploview where the r^2^threshold for capturing SNPs was set at 80%. The column labelled \"difference\" shows the actual increase in efficiency by Tagger due to its ability to replace some tag SNPs with multi-marker combinations of other tag SNPs \[[@B11]\]. The ratio of the number of tag SNPs to total number of variable SNPs (the last column of Table [2](#T2){ref-type="table"}) is a reflection of the LD variation in iron homeostasis genes. Table [3](#T3){ref-type="table"} examines the effect of varying the r^2^cutoff on the number of tagSNP for the six largest genes that were resequenced. The result from Tagger can vary betweens runs with identical settings so the lowest result from 10 runs is reported.

###### 

Comparison of number of tag SNPs generated by LDselect and Tagger in Haploview using Caucasian datasets (HAPMAP, NHLBI, Seattle SNPs). A \"test\" in Tagger refers to a combination of one to three tag SNPs used to capture one or more SNPs. The number of tests is the number of tag SNPs combinations required to capture all SNPs with a minimum value of r^2^of 80%. HapMap Phase 1 data was all that was available at the time of SNP selection.

                                **No. SNPs**    **Tagger**       **LDselect**   **Difference**   **Tags/Total Tagger**   **Tags/Total LDselect**
  ----------- ----------------- --------------- ---------------- -------------- ---------------- ----------------------- -------------------------
  **Gene**    **Data Source**   **MAF \> 3%**   **Tags/Tests**   **Tags**                                                
                                                                                                                         
  *ACO1*      HapMap            27              13/15            15             2                0.48                    0.56
  *CP*        HapMap            11              8/8              8              0                0.73                    0.73
  *CYBRD1*    HapMap            10              5/5              5              0                0.50                    0.50
              NHLBI RS&G        62              14/14            16             2                0.23                    0.26
  *FLVCR*     HapMap            17              6/8              8              2                0.35                    0.47
              NHLBI RS&G        99              16/19            17             1                0.16                    0.17
  *FTH1*      NHLBI RS&G        13              5/5              5              0                0.38                    0.38
  *HAMP*      NHLBI RS&G        7               4/4              4              0                0.57                    0.57
  *HCP1*      NHLBI RS&G        6               3/3              3              0                0.50                    0.50
  *HEPH*      HapMap            40              6/6              6              0                0.15                    0.15
  *IREB2*     HapMap            12              4/5              5              1                0.33                    0.42
  *SLC11A2*   HapMap            13              4/4              4              0                0.31                    0.31
  *SLC40A1*   HapMap            6               3/4              4              1                0.50                    0.67
  *TF*        HapMap            11              7/7              7              0                0.64                    0.64
              NHLBI RS&G        43              17/20            20             3                0.40                    0.47
              SeattleSNPs       101             29/31            31             2                0.29                    0.31
  *TFR2*      NHLBI RS&G        6               4/4              4              0                0.67                    0.67
  *TFRC*      HapMap            12              6/6              6              0                0.50                    0.50
              NHLBI RS&G        117             33/38            36             3                0.28                    0.31

###### 

Effect of varying r^2^on number of tagSNPs selected using Tagger and MAF≥3% for six genes using NHLBI resequencing data. First number is tagSNPs using 2 and 3 multi-marker SNP tagging, second number is number of tests (the number of unique combinations of tag SNPs required to represent all SNPs).

  r^2^   *TF*    *CYBRD1*   *ACO1*   *FLVCR*   *IREB2*   *TFRC*
  ------ ------- ---------- -------- --------- --------- --------
  0.50   10/10   9/9        19/21    8/8       10/11     22/22
  0.55   10/10   10/10      20/21    9/9       11/11     22/22
  0.60   11/11   12/14      21/23    10/10     11/11     25/25
  0.65   12/13   14/16      22/23    10/11     11/11     26/26
  0.70   14/16   15/15      22/23    11/12     11/11     27/28
  0.75   16/18   15/15      23/25    13/14     12/12     29/29
  0.80   17/19   15/15      23/26    15/17     12/12     33/36
  0.85   19/20   16/16      26/27    16/18     12/12     37/38
  0.90   19/21   18/21      27/32    17/18     12/12     42/43
  0.95   22/23   21/25      31/35    19/20     13/13     46/51
  1.00   23/36   21/25      34/37    22/27     14/15     50/52

Resequencing data versus HapMap
-------------------------------

Table [4](#T4){ref-type="table"} compares the number of tag SNPs (using LDselect) selected from NHLBI resequencing data and HapMap (both Caucasian samples). Using a minor allele frequency (MAF) ≥ 3%, there were two genes, *HFE2*and *FTH1*, for which there were no variable HapMap SNPs in the CEU population. Averaged across all the genes (in Table [4](#T4){ref-type="table"} the sum of NHLBI resequencing tag SNPs column divided by sum of HapMap tag SNPs column) there were 2.8 times as many tag SNPs required for resequencing cover than HapMap phase 1 due to the larger number of SNPs, especially of low frequency.

###### 

Number of tag SNPs from NHLBI resequencing versus HapMap data (Phase 1) for Europeans using MAF ≤ 3% and r^2^0.8.

  Gene       NHLBI RS&G   HapMap Phase 1
  ---------- ------------ ----------------
  *ACO1*     26           15
  *CYBRD1*   16           5
  *FLVCR*    17           8
  *FTH1*     5            0
  *HAMP*     4            1
  *HCP1*     3            1
  *HEPH*     13           6
  *HFE2*     5            0
  *IREB2*    11           5
  *PGRMC1*   5            1
  *PGRMC2*   2            2
  *TF*       20           7
  *TFR2*     4            2
  *TFRC*     36           6

Analysis of genotyping data for rs2239641 showed four data clusters rather than the usual three (for minor allele homozygotes, heterozygotes and major allele homozygotes). Using the resequencing data we were able to show that this inconsistency was due to a nearby (14 bp) untyped SNP causing two heterozygote clusters. For another pair of SNPs (TNFalpha rs1800630 and rs1800610) there were no compound heterozygotes. This may be due to an untyped SNP (rs1799724) 6 bp from rs1800630 causing the assay to fail when it is present. Illumina specifies a distance of 60 bp to reject two adjacent SNPs being included in the same OPA (oligo pool all). Resequencing can thus provide an additional exclusion criterion to avoid choosing as tagSNPs any SNP with another common SNP within 60 bp.

Transferrin as an example of the effect of resequencing coverage for tagSNP selection
-------------------------------------------------------------------------------------

Here we present an empirical example of the effect of resequencing coverage on the selection of tag SNPs. Figure [2](#F2){ref-type="fig"} shows the coverage of the transferrin gene (*TF*) by the four data sources. HealthIron resequencing data used only the exons and small amounts of the surrounding introns (at least 30 bp). The NHLBI RS&G data had a wider coverage (green) and SeattleSNPs coverage was nearly complete (black), with HapMap CEU SNPs in brown.

![**Regions sequenced in three resequencing Caucasian data sets: (i) HealthIron in red; (ii) NHLBI RS&G in green; (iii) SeattleSNPs in black**. The HapMap Phase 1 Caucasian (European) SNPs with MAF ≥ 3% rs numbers are shown. The *TF*gene appears in blue with the exons shown as bars. The arrows indicated the direction of transcription.](1471-2350-9-18-2){#F2}

Table [5](#T5){ref-type="table"} compares the number of SNPs with MAF ≥ 3% identified in data from Caucasians, using the four data sources (HealthIron, NHLBI RS&G, SeattleSNPS, and HapMap). The 7 HapMap tag SNPs, chosen from the 11 HapMap SNPs with MAF ≥ 3% using Tagger, capture just 45 out of the 101 Seattle SNPs (45%) using an r^2^threshold of 80% (so only 45% of SNPs have an r^2^of 0.80 or more with at least one tag SNP). Increasing the minimum MAF to 5% increases the capture of Seattle SNPs using HapMap tag SNPs to 48/89 (55%). Decreasing the r^2^threshold to 0.50 with minimum MAF still 3% only improved capture of the Seattle SNPs to 63/101 (62%). Approximately 55% of variant SNPs for transferrin in the SeattleSNPs database were not captured well using only HapMap phase 1 tag SNPs. In comparison HapMap Mar 2006 has 38 SNPs within the TF gene (MAF ≥ 3% in Caucasians), with 17 tag SNPs (pairwise using Tagger). Unfortunately *TF*was the only gene for which we could make this comparison, since it requires all the HapMap SNPs to be within the regions for which resequencing data are available. Figure [3](#F3){ref-type="fig"} shows the minor allele frequency of the captured and uncaptured SNPs, showing that there was an even frequency distribution of SNPs not captured, not just low frequency.

###### 

The number of SNPs identified for the transferrin gene from the four different data sources with different coverage. Figure 1 shows the coverage of each data set, N is the number of Caucasian individuals sequenced/typed.

                         Resequencing         HapMap              HapMap                                      
  ---------------------- -------------------- ------------------- -------------------- ---------------------- -----------------------
                         HealthIron N = 188   NHLBI RS&G N = 47   SeattleSNPs N = 23   N = 30 trios Phase 1   N = 30 trios Mar 2006
                                                                                                              
  Total No. SNPs         31                   59                  128                  12                     81
  No. SNPs ≥ 3% MAF      17                   43                  101                  11                     38
  Tag SNPs with Tagger   13                   20                  31                   7                      17

![**Frequency distribution of captured and uncaptured SNPs from Seattle resequencing of *TF*using HapMap tagSNPS**. The large number of captured SNPs in the 40--45% range represents the strong block of LD which is captured by a single tagSNP.](1471-2350-9-18-3){#F3}

Figure [4](#F4){ref-type="fig"} shows the additional detail that is available with increasing coverage of the SNP data in the same genomic region, from the coarse grain of the HapMap SNPs through to the fine grain of SeattleSNPs which approaches complete resequencing. While the major feature of a large block of LD on the righthand side of the display is apparent at all levels, there is much more detail with resequencing data and additional blocks of LD are revealed as more SNPs are added.

![**A graphical representation of linkage disequilibrium patterns for the transferrin gene from SNP data on Caucasian populations: (a) HapMap (11 SNPs with MAF ≥ 3%); (b) HealthIron (12 SNPs); (c) NHLBI RS&G (43 SNPs); (d) SeattleSNPs (101 SNPs)**. These LD displays were generated using the default settings in HaploView.](1471-2350-9-18-4){#F4}

Linkage disequilibrium patterns across five populations
-------------------------------------------------------

Table [6](#T6){ref-type="table"} lists the number of tag SNP and total number of SNPs with MAF ≥ 3% for 14 genes resequenced by NHLBI across five population samples. The ratio of tag to total SNPs is low for genes within which there is substantial LD (e.g. *FLVCR*). The number of tag SNPs required is higher for African populations due to both the higher total number of SNPs and lower LD for most genes (as shown by higher ratios of tag SNPs to total SNPs). The final column uses multiPopTagSelect \[[@B12]\] to choose a minimal union of population-specific tag SNPs to capture SNP variation across all five populations. Figure [5](#F5){ref-type="fig"} shows the pattern of linkage disequilibrium across five populations for the six genes which had more than 40 SNPs in each population. There is substantial variation in LD patterns both across genes and across populations which likely represents admixture variability throughout the genome.

###### 

Number of tag SNPs/total SNPs with MAF ≥ 3% (ratio) in each of five populations using LDSelect with NHLBI resequencing data. The last column shows number of tag SNPs and total SNPs combined across the five populations using multiPopTagSelect.

  Gene          European N = 47   Hipanic N = 48   Chinese N = 47   African American N = 24   Yoruban N = 24   Multiple
  ------------- ----------------- ---------------- ---------------- ------------------------- ---------------- ---------------
  *ACO1*        26/58 (0.45)      29/56 (0.52)     28/57 (0.49)     69/111 (0.62)             65/110 (0.59)    97/145 (0.67)
  *CYBRD1*      15/62 (0.24)      20/58 (0.34)     17/62 (0.27)     28/57 (0.49)              34/65 (0.52)     46/85 (0.54)
  *FLVCR*       17/99 (0.17)      11/75 (0.15)     8/83 (0.10)      18/82 (0.22)              18/91 (0.20)     27/114 (0.24)
  *FTH1*        5/13 (0.38)       10/17 (0.59)     4/7 (0.57)       11/19 (0.58)              8/14 (0.57)      17/27 (0.63)
  *HAMP*        4/7 (0.57)        4/7 (0.57)       7/10 (0.70)      8/10 (0.80)               9/11 (0.82)      11/15 (0.73)
  *HCP1*        3/6 (0.50)        5/9 (0.56)       4/9 (0.44)       11/16 (0.69)              11/15 (0.73)     17/22 (0.77)
  *HEPH*        13/38 (0.34)      10/36 (0.28)     9/10 (0.90)      16/58 (0.28)              21/53 (0.40)     49/95 (0.52)
  *HFE2*        5/7 (0.71)        5/8 (0.63)       4/7 (0.57)       8/10 (0.80)               5/7 (0.71)       10/13 (0.77)
  *IREB2*       11/52 (0.21)      11/47 (0.23)     15/63 (0.24)     21/94 (0.22)              18/95 (0.19)     42/134 (0.31)
  *PGRM1*       5/10 (0.50)       2/2 (1.00)       0/0              8/11 (0.73)               10/13 (0.77)     15/19 (0.79)
  *PGRM2*       2/4 (0.50)        4/8 (0.50)       7/9 (0.78)       10/13 (0.77)              11/17 (0.65)     16/22 (0.73)
  *TF*          20/44 (0.45)      24/50 (0.48)     17/49 (0.35)     34/61 (0.56)              42/61 (0.69)     61/87 (0.70)
  *TFR2*        4/6 (0.67)        3/5 (0.60)       5/7 (0.71)       5/5 (1.00)                6/7 (0.86)       8/9 (0.89)
  *TFRC*        36/119 (0.30)     34/115 (0.30)    22/93 (0.24)     43/135 (0.32)             44/110 (0.40)    87/187 (0.47)
  Av No. tags   11.9              12.3             10.5             20.7                      21.6             35.9

![Pattern of linkage disequilibrium across six genes and five population samples using Haploview default settings (with blocks removed).](1471-2350-9-18-5){#F5}

We found the average capture rate of SNPs with MAF ≥ 3% across 10 genes (*TF, TFR2, CYBRD1, FTH1, HAMP, HFE2, HCP1, IREB2, FLVCR*and *ACO1*) in the Hispanic population using European tags was 82.5% (using NHLBI data i.e. 47 European descent, 48 Hispanic descent), and for the African American sample using Yoruban tags 78.1% (data not shown). However, there was one gene (*FTH1*) whose capture rate was \< 50% for both comparisons. The capture rate of Yoruban SNPs using European tag SNPs was poor, an average of 35% over 10 genes, range 14--60% (data not shown).

Coverage of stock genotyping arrays
-----------------------------------

To compare our findings with the coverage that would be achieved with the \"standard\" Affymetrix and Illumina genotyping arrays, the number of SNPs appearing across various genotyping arrays within the regions for which we did partial resequencing are displayed in Table [7](#T7){ref-type="table"}. While this is not a direct comparison of true coverage, which would require complete resequencing information, arrays with less than the number of tagSNPs cannot meet our coverage criteria of r^2^≥ 0.8 for SNP with MAF ≥ 3%. TFRC needed a higher number of tagSNPs than the number of SNPs present even on the latest array versions. HCP1 (previously known as MGC9564) has no SNPs on Affymetrix arrays.

###### 

Number of SNPs on different genotyping arrays within each gene region of NHLBI resequencing. Note that in all cases the entire region was not resequenced and so the first two columns are conservative and refer only to the sample of 47 people of European descent.

  Gene       NHLBI reseq total SNPs   NHLBI tagSNPs MAF≥3% r2 0.8   Region included in basepairs   Affy 100K   Affy 500K   Affy GW5   Affy GW6   Illumina Humhap 300   Illumina Humhap 550   Illumina Human 1M
  ---------- ------------------------ ----------------------------- ------------------------------ ----------- ----------- ---------- ---------- --------------------- --------------------- -------------------
  *ACO1*     276                      26                            69937                          1           11          12         24         14                    26                    41
  *CYBRD1*   139                      16                            39535                          0           3           3          8          7                     12                    19
  *FLVCR*    185                      17                            40442                          4           6           6          15         11                    12                    18
  *HAMP*     43                       4                             6314                           0           2           2          3          1                     1                     4
  *HCP1*     65                       3                             11169                          0           0           0          0          1                     2                     7
  *HEPH*     177                      13                            101478                         1           11          10         32         5                     7                     21
  *HFE2*     38                       5                             7437                           0           1           1          2          0                     1                     5
  *IREB2*    241                      11                            64450                          1           15          11         21         3                     7                     24
  *PGRMC1*   33                       5                             12051                          0           0           0          1          1                     1                     7
  *PGRMC2*   55                       2                             21640                          0           1           1          4          2                     3                     9
  *TF*       158                      20                            33189                          0           23          18         37         8                     11                    23
  *TFR2*     56                       4                             21649                          0           0           0          1          3                     3                     13
  *TFRC*     314                      36                            36402                          2           4           4          10         7                     8                     14

Discussion
==========

We have reported on the challenges we faced in selecting SNPs from candidate genes of iron metabolism for genotyping in an association study. At the time we were required to make the SNP selection for the HealthIron study, resequencing data from the same participants was available for only 6 genes, and the coverage based on this local sample included only the exons and immediate surrounding genomic regions. We turned instead to several public available databases, including the International HapMap and Seattle SNPs projects, and the NHLBI RS&G data analysed for the HEIRS ancillary study on iron deficiency. Data from the NHLBI RS&G project identified SNPs for 14 genes (asterisked in Table [1](#T1){ref-type="table"}). There were 32 novel SNPs not in dbSNP (so without *rs*numbers) included in the HealthIron tag SNP list.

The benefits of resequencing for genetic data include detection of novel SNPs, a more detailed coverage of the candidate genes, as indicated by the higher number of tag SNPs generated from resequencing data in comparison to the HapMap (2.8 times over 14 genes), and knowledge of the precise pattern of LD in the population of interest. We included some genes in our study that did not have any variable SNPs in the HapMap phase 1 database.

The transferability of tag SNPs has received considerable attention recently, with reports of good performance of European (CEU) tag SNPs in populations from the United Kingdom \[[@B13]\], Finland, Estonia \[[@B14]\]and the Pacific Rim (in particular Japanese, Chinese, Hawaiian and Latino)\[[@B15]\]. We confirmed the finding of de Bakker et al. \[[@B11]\] that European tag SNPs performed poorly in the African population, capturing only an average of 35% of SNP variation. Our results are also consistent with those of Tantoso et al. \[[@B16]\], who found that the SNPs in the HapMap capture only about 55% of untyped variants. For the transferrin gene, using the SeattleSNPs database we found 45% of SNPs with MAF ≥ 3% were captured by HapMap tag SNPs.

Although the cross-population tagging rate for the Hispanic population using European tags (83%) and African American using Yoruban tags (78%) was high for nine of the ten genes, there was one gene (*FTH1*) for which the capture rate was less than 50%. For candidate gene/region studies where there is strong a priori evidence of association, an exhaustive SNP search is desirable and hence using tag SNPs selected from a different population may result in a failure to genotype any markers in strong LD with a causative variant. This variability is likely to represent admixture variability throughout the genome. Some of these population differences may reflect different selection history among populations due to diet or disease prevalence that may be relevant in a genetic association study.

A sensible approach to overcoming the problem in of selecting tag SNPs in multi-ethnic cohort studies is to use an optimal union of population-specific tag SNPs as implemented in the program multiPopTagSelect \[[@B12]\]. Although this resulted in a three fold increase in the number of tag SNPs required to capture all five populations in the NHLBI RS&G database compared to selected tag SNPs in the European sub-population alone, it was a still a substantial reduction compared to the additional genotyping that would have been required if selection had been performed independently within each population. The algorithm proposed by Howie et al. (2006) leverages the existing results of LDselect within separate population samples, and can easily accommodate tag SNPs ranked by a performance criterion such as the validation scores with which we were provided for use with the Illumina genotyping platform. In contrast, it was time-consuming to determine \"manually\" the set of tag SNPs with the highest possible combined validation score using Tagger, since it makes no use of these scores with the exception that SNPs with validation scores below a threshold can be excluded from consideration. In hindsight it would have been quicker to use LDselect alone for this particular collection of candidate genes, as the difference in tag SNPs selected was small relative to the amount of time spent rerunning Tagger. The previously reported increase in efficiency of Tagger using two and three tag SNPs combinations \[[@B11]\] also potentially requires more complex analysis than single SNP associations. Tagger should be rerun several times as the number of tagSNPs required may vary between runs with identical settings.

Conclusion
==========

When selecting SNPs for genotyping in association studies, the candidate gene approach is distinct from the whole genome scanning approach which only examines common SNPs. For candidate genes it is preferable to augment HapMap data with sequence data. This has the advantage of aiding in the discovery and coverage of SNPs with frequencies in the range of 1% to 5% which are unlikely to appear in the HapMap database. Remaining challenges in SNP selection within candidate genes include developing methods for combining multiple sources of information and incorporating redundancy to overcome platform limitations.
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